BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 38491867)

  • 1. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford ED; Kopyltsov E; Park CH; Alekseev B; Montesa-Pino Á; Ye D; Parnis F; Cruz F; Tammela TLJ; Suzuki H; Utriainen T; Fu C; Uemura M; Méndez-Vidal MJ; Maughan BL; Joensuu H; Thiele S; Li R; Kuss I; Tombal B;
    N Engl J Med; 2022 Mar; 386(12):1132-1142. PubMed ID: 35179323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    Hussain M; Tombal B; Saad F; Fizazi K; Sternberg CN; Crawford ED; Shore N; Kopyltsov E; Kalebasty AR; Bögemann M; Ye D; Cruz F; Suzuki H; Kapur S; Srinivasan S; Verholen F; Kuss I; Joensuu H; Smith MR
    J Clin Oncol; 2023 Jul; 41(20):3595-3607. PubMed ID: 36795843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Buck SAJ; Talebi Z; Drabison T; Jin Y; Gibson AA; Hu P; de Bruijn P; de Ridder CMA; Stuurman D; Hu S; van Weerden WM; Koolen SLW; de Wit R; Sparreboom A; Mathijssen RHJ; Eisenmann ED
    Int J Cancer; 2024 Jul; 155(2):314-323. PubMed ID: 38491867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
    Lee A
    Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.
    Podgoršek E; Mehra N; van Oort IM; Somford DM; Boerrigter E; van Erp NP
    Clin Pharmacokinet; 2023 Aug; 62(8):1049-1061. PubMed ID: 37458966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.